Compare Lululemon Athletica Inc (LULU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs TG Therapeutics Inc — how do they compare? Lululemon Athletica Inc trades at $115 (market cap $13.25B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Lululemon Athletica Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| LULU | TGTX | |
|---|---|---|
Market Cap | $13.25B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $224.03 | $59.06 |
52-Week Low | $105.43 | $26.39 |
Enterprise Value | $13.87B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon trades at $116.79, up 0.4% on the day, with a bearish technical signal but strong fundamentals including a 13.03% net margin and 32.03% ROE. Recent earnings beats and a $30M investment in nylon recycling startup Syntetica highlight growth initiatives, though the stock faces headwinds from North American weakness and a class-action lawsuit over tariff costs. The current price sits near pivot point resistance at $117.
The outlook is mixed: valuation metrics like a 9.42 P/E suggest potential upside to the $129.29 consensus target, but bearish technicals and competitive pressures pose risks. Investment opportunity lies in robust cash flow and buyback potential, while key risks include brand controversies and macroeconomic sensitivity.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
